よむ、つかう、まなぶ。
03【資料１】新型コロナワクチンの接種について (48 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_27963.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会（第37回 9／14）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
参考資料一覧（1/4）
2022年秋以降の新型コロナワクチン追加接種及びオミクロン株対応ワクチンの接種に係る諸外国の状況
米国
CDC. 2022. CDC Recommends the First Updated COVID-19 Booster. [online] Available at: <https://www.cdc.gov/media/releases/2022/s0901-covid-19-booster.html> [Accessed 13 Sep 2022].
U.S. Food and Drug Administration. 2022. Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose. [online] Available at: <https://www.fda.gov/news-events/pressannouncements/coronavirus-covid-19-update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use> [Accessed 13 Sep 2022].
英国
GOV.UK. 2022. JCVI statement on the COVID-19 booster vaccination programme for autumn 2022: update 3 September 2022. [online] Available at: <https://www.gov.uk/government/publications/covid-19-vaccines-for-autumn2022-jcvi-advice-15-august-2022/jcvi-statement-on-the-covid-19-booster-vaccination-programme-for-autumn-2022-update-15-august-2022> [Accessed Sep 13, 2022].
カナダ
NACI. 2022. Recommendations on the use of bivalent Omicroncontaining mRNA COVID-19 vaccines. [online] Available at:
<https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-bivalent-Omicron-containing-mrna-covid-19-vaccines.pdf> [Accessed 13 Sep 2022].
NACI. 2022. Interim guidance on planning considerations for a fall 2022 COVID-19 vaccine booster program in Canada. [online] Available at: <https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisorycommittee-on-immunization-naci/naci-guidance-planning-fall-2022-covid-19-vaccine-booster.pdf> [Accessed 13 Sep 2022].
フランス
Haute Autorité de Santé. 2022. Avis n°2022.0036/AC/SESPEV du 16 juin 2022 du collège de la Haute Autorité de santé relatif au lancement de la campagne de vaccination 2022/2023 contre la grippe saisonnière en France dans l’hémisphère
Nord et à Mayotte dans le contexte de l’épidémie de Covid-19. [online] Available at: <https://www.has-sante.fr/jcms/p_3345196/fr/avis-n2022-0036/ac/sespev-du-16-juin-2022-du-college-de-la-haute-autorite-de-sante-relatif-au-lancement-de-lacampagne-de-vaccination-2022/2023-contre-la-grippe-saisonniere-en-france-dans-l-hemisphere-nord-et-a-mayotte-dans-le-contexte-de-l-epidemie-de-covid-19> [Accessed 21 July 2022].
イスラエル
Ministry of Health. 2022. [online] Available at: <https://www.gov.il/BlobFolder/reports/ect-12062022/he/files_publications_units_epidemic_control_ect-12062022.pdf> [Accessed 21 July 2022].
国際連合
WHO. 2022. Interim statement on the composition of current COVID-19 vaccines. [online] Available at: <https://www.who.int/news/item/17-06-2022-interim-statement-on--the-composition-of-current-COVID-19-vaccines> [Accessed 21 July 2022].
WHO. 2022. Interim statement on the use of additional booster doses of Emergency Use Listed mRNA vaccines against COVID-19. [online] Available at: <https://www.who.int/news/item/17-05-2022-interim-statement-on-the-use-of-additionalbooster-doses-of-emergency-use-listed-mrna-vaccines-against-covid-19> [Accessed 21 July 2022].
EU
EMA. 2022. ECDC-EMA statement on booster vaccination with Omicron adapted bivalent COVID-19 vaccines. [online] Available at: < https://www.ema.europa.eu/en/documents/public-statement/ecdc-ema-statement-booster-vaccination-omicronadapted-bivalent-covid-19-vaccines_-0.pdf > [Accessed 13 Sep 2022].
48
2022年秋以降の新型コロナワクチン追加接種及びオミクロン株対応ワクチンの接種に係る諸外国の状況
米国
CDC. 2022. CDC Recommends the First Updated COVID-19 Booster. [online] Available at: <https://www.cdc.gov/media/releases/2022/s0901-covid-19-booster.html> [Accessed 13 Sep 2022].
U.S. Food and Drug Administration. 2022. Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose. [online] Available at: <https://www.fda.gov/news-events/pressannouncements/coronavirus-covid-19-update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use> [Accessed 13 Sep 2022].
英国
GOV.UK. 2022. JCVI statement on the COVID-19 booster vaccination programme for autumn 2022: update 3 September 2022. [online] Available at: <https://www.gov.uk/government/publications/covid-19-vaccines-for-autumn2022-jcvi-advice-15-august-2022/jcvi-statement-on-the-covid-19-booster-vaccination-programme-for-autumn-2022-update-15-august-2022> [Accessed Sep 13, 2022].
カナダ
NACI. 2022. Recommendations on the use of bivalent Omicroncontaining mRNA COVID-19 vaccines. [online] Available at:
<https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-bivalent-Omicron-containing-mrna-covid-19-vaccines.pdf> [Accessed 13 Sep 2022].
NACI. 2022. Interim guidance on planning considerations for a fall 2022 COVID-19 vaccine booster program in Canada. [online] Available at: <https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisorycommittee-on-immunization-naci/naci-guidance-planning-fall-2022-covid-19-vaccine-booster.pdf> [Accessed 13 Sep 2022].
フランス
Haute Autorité de Santé. 2022. Avis n°2022.0036/AC/SESPEV du 16 juin 2022 du collège de la Haute Autorité de santé relatif au lancement de la campagne de vaccination 2022/2023 contre la grippe saisonnière en France dans l’hémisphère
Nord et à Mayotte dans le contexte de l’épidémie de Covid-19. [online] Available at: <https://www.has-sante.fr/jcms/p_3345196/fr/avis-n2022-0036/ac/sespev-du-16-juin-2022-du-college-de-la-haute-autorite-de-sante-relatif-au-lancement-de-lacampagne-de-vaccination-2022/2023-contre-la-grippe-saisonniere-en-france-dans-l-hemisphere-nord-et-a-mayotte-dans-le-contexte-de-l-epidemie-de-covid-19> [Accessed 21 July 2022].
イスラエル
Ministry of Health. 2022. [online] Available at: <https://www.gov.il/BlobFolder/reports/ect-12062022/he/files_publications_units_epidemic_control_ect-12062022.pdf> [Accessed 21 July 2022].
国際連合
WHO. 2022. Interim statement on the composition of current COVID-19 vaccines. [online] Available at: <https://www.who.int/news/item/17-06-2022-interim-statement-on--the-composition-of-current-COVID-19-vaccines> [Accessed 21 July 2022].
WHO. 2022. Interim statement on the use of additional booster doses of Emergency Use Listed mRNA vaccines against COVID-19. [online] Available at: <https://www.who.int/news/item/17-05-2022-interim-statement-on-the-use-of-additionalbooster-doses-of-emergency-use-listed-mrna-vaccines-against-covid-19> [Accessed 21 July 2022].
EU
EMA. 2022. ECDC-EMA statement on booster vaccination with Omicron adapted bivalent COVID-19 vaccines. [online] Available at: < https://www.ema.europa.eu/en/documents/public-statement/ecdc-ema-statement-booster-vaccination-omicronadapted-bivalent-covid-19-vaccines_-0.pdf > [Accessed 13 Sep 2022].
48